L&C BIOLTD (A290650) Stock Overview
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
A290650 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
L&C BIO Co.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩78,700.00 |
| 52 Week High | ₩125,000.00 |
| 52 Week Low | ₩18,490.00 |
| Beta | 1.45 |
| 1 Month Change | -17.94% |
| 3 Month Change | 8.25% |
| 1 Year Change | 266.05% |
| 3 Year Change | 217.34% |
| 5 Year Change | 116.21% |
| Change since IPO | 776.07% |
Recent News & Updates
Recent updates
L&C BIO Co.,LTD's (KOSDAQ:290650) P/S Is Still On The Mark Following 51% Share Price Bounce
Jan 30
L&C BIO Co.,LTD's (KOSDAQ:290650) Price In Tune With Revenues
Nov 29L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some Questions
Apr 01There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price Rise
Dec 14Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?
Nov 12Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden
Aug 06What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You
Jul 05L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions
Mar 27Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?
Apr 20L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality
Apr 01Is L&C Bio (KOSDAQ:290650) A Risky Investment?
Mar 02Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year
Feb 03What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?
Jan 04Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?
Dec 08Shareholder Returns
| A290650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.0% | 0.2% | -1.6% |
| 1Y | 266.0% | 38.7% | 106.8% |
Return vs Industry: A290650 exceeded the KR Biotechs industry which returned 38.7% over the past year.
Return vs Market: A290650 exceeded the KR Market which returned 106.8% over the past year.
Price Volatility
| A290650 volatility | |
|---|---|
| A290650 Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in KR Market | 15.4% |
| 10% least volatile stocks in KR Market | 4.2% |
Stable Share Price: A290650's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A290650's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 141 | Chul Lee Whan | www.lncbio.co.kr |
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.
L&C BIO Co.,LTD Fundamentals Summary
| A290650 fundamental statistics | |
|---|---|
| Market cap | ₩1.98t |
| Earnings (TTM) | ₩78.71b |
| Revenue (TTM) | ₩79.99b |
Is A290650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A290650 income statement (TTM) | |
|---|---|
| Revenue | ₩79.99b |
| Cost of Revenue | ₩38.63b |
| Gross Profit | ₩41.36b |
| Other Expenses | -₩37.35b |
| Earnings | ₩78.71b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.17k |
| Gross Margin | 51.70% |
| Net Profit Margin | 98.39% |
| Debt/Equity Ratio | 35.4% |
How did A290650 perform over the long term?
See historical performance and comparisonDividends
Does A290650 pay a reliable dividends?
See A290650 dividend history and benchmarks| L&C BIOLTD dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Apr 15 2026 |
| Days until Ex dividend | 78 days |
| Days until Dividend pay date | 29 days |
Does A290650 pay a reliable dividends?
See A290650 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/16 16:00 |
| End of Day Share Price | 2026/03/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
L&C BIO Co.,LTD is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chae-eun Lee | Eugene Investment & Securities Co Ltd. |
| SungKyu Heo | Shinhan Investment Corp. |
| Seung-eun Lee | Yuanta Securities Korea Co., Ltd. |